LAUSR

OBJECTIVE To systematically evaluate and quantify the effects of rotigotine treatment on neuropsychiatric symptoms in Parkinson's disease (PD). METHODS We searched for articles involving randomized controlled trials (RCTs) that were published before September 1, 2017, in the PubMed, Clinical Trials, Cochrane Library, and EMBASE databases. A meta-analysis was performed to estimate changes in the scales used to assess neuropsychiatric symptoms. The data were analyzed using Cochrane Collaboration's Review Manager 5.3 software. RESULTS We identified 8 RCTs involving 1675 subjects. Compared with placebo treatment, treatment with the rotigotine transdermal patch significantly improved scores for the emotion/apathy domains of the Non-Motor Symptoms Scale (NMSS), Beck Depression Inventory-II (BDI-II), Apathy Scale (AS), the sleep/fatigue domains of the NMSS, the 8-item Parkinson's disease Questionnaire (PDQ-8) and the 39-item PDQ (PDQ-39) (emotion/apathy domain of the NMSS: MD = -2.5, 95% CI [-4.11, 0.89]; BDI-II: MD = -1.19, 95% CI [-2.30, 0.08]; AS: MD = -1.56, 95% CI [-2.67, 0.45]; sleep/fatigue domain of the NMSS: MD = -2.03, 95% CI [-3.08, 0.98]; PDQ-8: MD = -4.93, 95% CI [-6.79, 3.07]; PDQ-39: MD = -3.52, 95% CI [-5.25, 1.79]; PDQ-8 and PDQ-39: SMD = -0.36,95% CI [-0.49,0.23]). The results of the Parkinson's Disease Sleep Scale 2nd version (PDSS-2) were heterogeneous, and those on the Snaith-Hamilton Pleasure Scale (SHAPS) were not statistically significant (P = .61). CONCLUSION The rotigotine transdermal patch effectively improved neuropsychiatric symptoms and quality of life in patients with PD. Further studies are warranted.